• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脂蛋白(a)与股腘动脉病变血管造影严重程度的关系。

Relationship Between Lipoprotein(a) and Angiographic Severity of Femoropopliteal Lesions.

机构信息

Department of Cardiovascular and Renal Medicine, Hyogo College of Medicine.

出版信息

J Atheroscler Thromb. 2021 May 1;28(5):555-561. doi: 10.5551/jat.56457. Epub 2020 Aug 29.

DOI:10.5551/jat.56457
PMID:32863296
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8193776/
Abstract

AIM

High levels of lipoprotein(a) [Lp(a)] are a risk factor for peripheral artery disease (PAD). However, the relationship between Lp(a) levels and the severity of femoropopliteal lesions in patients with PAD has not been systematically studied. This study aimed to assess the impact of Lp(a) levels on angiographic severity of femoropopliteal lesions in patients with PAD.

METHODS

We retrospectively analyzed a single-center database including 108 patients who underwent endovascular therapy for de novo femoropopliteal lesions and measured the Lp(a) levels before therapy between June 2016 and September 2019. Patients were divided into low Lp(a) [Lp(a) <30 mg/dL; 77 patients] and high Lp(a) [Lp(a) ≥ 30 mg/dL; 31 patients] groups. Trans-Atlantic Inter-Society Consensus (TASC) II classification, calcification [referring to the peripheral arterial calcium scoring system (PACSS) classification], and lesion length were compared between the groups.

RESULTS

The prevalence of TASC II class D (13% vs 38%, P<0.01) and severe calcification (PACSS 4) (6% vs 23%, P=0.02) was significantly higher and the lesion length longer (123±88 mm vs 175±102 mm, P<0.01) in the high Lp(a) group than in the low Lp(a) group. In multivariate analysis, Lp(a) ≥ 30 was an independent predictor for the prevalence of TASC II class D (HR=3.67, 95% CI 1.27-10.6, P=0.02) and PACSS 4 (HR=4.97, 95% CI 1.27-19.4, P=0.02).

CONCLUSION

The prevalence of TASC II class D and severe calcification of femoropopliteal lesions was higher in patients with high Lp(a) than those with low Lp(a).

摘要

目的

脂蛋白(a)[Lp(a)]水平升高是外周动脉疾病(PAD)的危险因素。然而,Lp(a)水平与 PAD 患者股腘病变严重程度之间的关系尚未得到系统研究。本研究旨在评估 Lp(a)水平对 PAD 患者股腘病变血管造影严重程度的影响。

方法

我们回顾性分析了 2016 年 6 月至 2019 年 9 月期间在单中心接受腔内治疗的 108 例新发股腘病变患者的数据库,在治疗前测量了 Lp(a)水平。患者分为低 Lp(a)[Lp(a)<30mg/dL;77 例]和高 Lp(a)[Lp(a)≥30mg/dL;31 例]组。比较两组患者的跨大西洋内科学会共识(TASC)II 分类、钙化[指外周动脉钙评分系统(PACSS)分类]和病变长度。

结果

高 Lp(a)组 TASC II 级 D(13%比 38%,P<0.01)和严重钙化(PACSS 4)(6%比 23%,P=0.02)的发生率明显更高,病变长度更长(123±88mm 比 175±102mm,P<0.01)。多变量分析显示,Lp(a)≥30 是 TASC II 级 D(HR=3.67,95%CI 1.27-10.6,P=0.02)和 PACSS 4(HR=4.97,95%CI 1.27-19.4,P=0.02)的独立预测因子。

结论

高 Lp(a)患者的 TASC II 级 D 和股腘病变严重钙化的发生率高于低 Lp(a)患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f8a/8193776/a7d1ce0e237e/28_56457_1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f8a/8193776/a7d1ce0e237e/28_56457_1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f8a/8193776/a7d1ce0e237e/28_56457_1.jpg

相似文献

1
Relationship Between Lipoprotein(a) and Angiographic Severity of Femoropopliteal Lesions.脂蛋白(a)与股腘动脉病变血管造影严重程度的关系。
J Atheroscler Thromb. 2021 May 1;28(5):555-561. doi: 10.5551/jat.56457. Epub 2020 Aug 29.
2
Impact of lipoprotein(a) levels on primary patency after endovascular therapy for femoropopliteal lesions.脂蛋白(a)水平对股腘病变腔内治疗后一期通畅率的影响。
Heart Vessels. 2023 Feb;38(2):171-176. doi: 10.1007/s00380-022-02151-7. Epub 2022 Jul 29.
3
Shared and differential factors influencing restenosis following endovascular therapy between TASC (Trans-Atlantic Inter-Society Consensus) II class A to C and D lesions in the femoropopliteal artery.影响股腘动脉 TASC II 分级 A 至 C 和 D 病变腔内治疗后再狭窄的共同和差异因素。
JACC Cardiovasc Interv. 2014 Jul;7(7):792-8. doi: 10.1016/j.jcin.2014.01.168.
4
Inverse association of diabetes and dialysis with the severity of femoropopliteal lesions and chronic total occlusion: a cross-sectional study of 2056 cases.糖尿病和透析与股腘病变和慢性完全闭塞严重程度的反比关联:2056 例的横断面研究。
BMC Cardiovasc Disord. 2020 Dec 9;20(1):514. doi: 10.1186/s12872-020-01805-6.
5
Impact of Calcification on Clinical Outcomes After Endovascular Therapy for Superficial Femoral Artery Disease: Assessment Using the Peripheral Artery Calcification Scoring System.钙化对股浅动脉疾病血管内治疗后临床结局的影响:使用外周动脉钙化评分系统进行评估
J Endovasc Ther. 2016 Oct;23(5):731-7. doi: 10.1177/1526602816656612. Epub 2016 Jul 1.
6
Patterns of femoropopliteal recurrence after routine and selective stenting endoluminal therapy.常规和选择性支架血管成形术腔内治疗后股浅动脉再狭窄的模式。
J Vasc Surg. 2013 Jan;57(1):37-43. doi: 10.1016/j.jvs.2012.06.097. Epub 2012 Sep 10.
7
Retrospective Multicenter Comparison Between Viabahn Covered Stent-Grafts and Supera Interwoven Nitinol Stents for Endovascular Treatment in Severely Calcified Femoropopliteal Artery Disease: The ARMADILLO Study (Adjusted Retrospective coMparison of scAffolDs In caLcified LesiOns).回顾性多中心比较 Viabahn 覆膜支架和 Supera 编织型镍钛合金支架治疗严重钙化股腘动脉病变的疗效:ARMADILLO 研究(调整后的回顾性比较支架在钙化病变中的应用)。
J Endovasc Ther. 2024 Jun;31(3):400-409. doi: 10.1177/15266028221124727. Epub 2022 Sep 22.
8
Comparison of Endovascular Versus Bypass Surgery in Femoropopliteal TASC II D Lesions: A Single-Center Study.股腘动脉TASC II D型病变的血管内治疗与旁路手术比较:一项单中心研究
Ann Vasc Surg. 2018 Feb;47:179-187. doi: 10.1016/j.avsg.2017.09.008. Epub 2017 Sep 22.
9
Comparison of Clinical Outcomes between Endovascular Therapy with Self-Expandable Nitinol Stent and Femoral-Popliteal Bypass for Trans-Atlantic Inter-Society Consensus II C and D Femoropopliteal Lesions.自膨式镍钛合金支架血管内治疗与股腘动脉旁路移植术治疗跨大西洋两岸血管外科学会(TASC)II C型和D型股腘动脉病变的临床结局比较
Ann Vasc Surg. 2019 May;57:137-143. doi: 10.1016/j.avsg.2018.09.024. Epub 2018 Nov 27.
10
Lipoprotein(a) is a risk factor for aortic and mitral valvular stenosis in peripheral arterial disease.脂蛋白(a)是外周动脉疾病主动脉瓣和二尖瓣狭窄的一个危险因素。
Eur Heart J Cardiovasc Imaging. 2016 May;17(5):492-7. doi: 10.1093/ehjci/jev338. Epub 2016 Jan 12.

引用本文的文献

1
Prognostic value of lipoprotein(a) for cardiovascular events after lower limb revascularization in diabetic patients with chronic limb-threatening ischemia.脂蛋白(a)对慢性肢体威胁性缺血的糖尿病患者下肢血管重建术后心血管事件的预后价值。
Cardiovasc Diabetol. 2025 Jul 10;24(1):271. doi: 10.1186/s12933-025-02833-2.
2
Peripheral arterial disease associated with elevated lipoprotein(a): a review of the evidence and treatment approaches.与脂蛋白(a)升高相关的外周动脉疾病:证据与治疗方法综述
Curr Opin Lipidol. 2025 May 26. doi: 10.1097/MOL.0000000000000999.
3
Association between lipoprotein (a) and risk of atherosclerotic cardiovascular disease events among maintenance hemodialysis patients in Beijing, China: a single-center, retrospective study.

本文引用的文献

1
Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement.血管钙化是 Zilver PTX 紫杉醇涂层支架置入治疗复杂股腘动脉病变后支架内再狭窄的危险因素。
J Endovasc Ther. 2019 Oct;26(5):613-620. doi: 10.1177/1526602819860124. Epub 2019 Jul 1.
2
Plasma Lipoprotein(a) Concentration Is Associated With the Coronary Severity but Not With Events in Stable Coronary Artery Disease Patients: A Chinese Cohort Study.血浆脂蛋白(a)浓度与冠状动脉严重程度相关,但与稳定型冠状动脉疾病患者的事件无关:一项中国队列研究。
Heart Lung Circ. 2019 Jul;28(7):1009-1017. doi: 10.1016/j.hlc.2018.05.190. Epub 2018 Jun 8.
3
脂蛋白(a)与中国北京维持性血液透析患者动脉粥样硬化性心血管疾病事件风险的关系:一项单中心回顾性研究。
BMC Nephrol. 2024 Aug 1;25(1):250. doi: 10.1186/s12882-024-03690-z.
4
Epidemiology of atherosclerotic cardiovascular disease in polygenic hypercholesterolemia with or without high lipoprotein(a) levels.伴有或不伴有高脂蛋白(a)水平的多基因高胆固醇血症中动脉粥样硬化性心血管疾病的流行病学
Front Cardiovasc Med. 2024 Jan 22;10:1272288. doi: 10.3389/fcvm.2023.1272288. eCollection 2023.
5
Association between lipoprotein(a) and peripheral arterial disease in coronary artery bypass grafting patients.脂蛋白(a)与冠状动脉旁路移植术患者外周动脉疾病的关系。
Clin Cardiol. 2023 May;46(5):512-520. doi: 10.1002/clc.24003. Epub 2023 Mar 10.
6
Association of Smoking, Diabetes, and Dialysis with the Presence of Popliteal Lesions in Femoropopliteal Artery Disease.吸烟、糖尿病和透析与股腘动脉疾病中腘部病变的相关性
J Atheroscler Thromb. 2023 Oct 1;30(10):1327-1335. doi: 10.5551/jat.64007. Epub 2022 Dec 29.
7
Effect of Omega-3 Fatty Acid Supplementation on the Postprandial Metabolism of Apolipoprotein(a) in Familial Hypercholesterolemia.ω-3 脂肪酸补充剂对家族性高胆固醇血症患者载脂蛋白(a)餐后代谢的影响。
J Atheroscler Thromb. 2023 Mar 1;30(3):274-286. doi: 10.5551/jat.63587. Epub 2022 Jun 8.
Lipoprotein (a) levels and outcomes in stable outpatients with symptomatic artery disease.
脂蛋白(a)水平与有症状动脉疾病稳定门诊患者的结局。
Atherosclerosis. 2018 Sep;276:10-14. doi: 10.1016/j.atherosclerosis.2018.07.001. Epub 2018 Jul 4.
4
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).依洛尤单抗降低低密度脂蛋白胆固醇水平及外周动脉疾病患者的结局:来自 FOURIER 试验(在高风险人群中用 PCSK9 抑制剂进行进一步心血管结局研究)的见解。
Circulation. 2018 Jan 23;137(4):338-350. doi: 10.1161/CIRCULATIONAHA.117.032235. Epub 2017 Nov 13.
5
Twenty-Year Predictors of Peripheral Arterial Disease Compared With Coronary Heart Disease in the Scottish Heart Health Extended Cohort (SHHEC).20 年预测外周动脉疾病与苏格兰心脏健康扩展队列(SHHEC)中的冠心病比较。
J Am Heart Assoc. 2017 Sep 18;6(9):e005967. doi: 10.1161/JAHA.117.005967.
6
Clinical outcomes of balloon angioplasty alone versus nitinol stent implantation in patients with small femoropopliteal artery disease: Observations from the Retrospective Multicenter Analysis for Femoropopliteal Stenting (REAL-FP).单纯球囊血管成形术与镍钛诺支架植入术治疗小股腘动脉疾病患者的临床结局:来自股腘动脉支架置入回顾性多中心分析(REAL-FP)的观察结果
Catheter Cardiovasc Interv. 2017 Nov 1;90(5):790-797. doi: 10.1002/ccd.27192. Epub 2017 Jul 19.
7
A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies.在语境中检验:脂蛋白(a):诊断、预后、争议和新兴疗法。
J Am Coll Cardiol. 2017 Feb 14;69(6):692-711. doi: 10.1016/j.jacc.2016.11.042.
8
Impact of Calcification on Clinical Outcomes After Endovascular Therapy for Superficial Femoral Artery Disease: Assessment Using the Peripheral Artery Calcification Scoring System.钙化对股浅动脉疾病血管内治疗后临床结局的影响:使用外周动脉钙化评分系统进行评估
J Endovasc Ther. 2016 Oct;23(5):731-7. doi: 10.1177/1526602816656612. Epub 2016 Jul 1.
9
Relationship Between Primary Patency and Lesion Length Following Bare Nitinol Stent Placement for Femoropopliteal Disease.裸镍钛合金支架置入治疗股腘动脉疾病后原发性通畅率与病变长度的关系
J Endovasc Ther. 2015 Dec;22(6):862-7. doi: 10.1177/1526602815610118. Epub 2015 Oct 5.
10
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.依洛尤单抗降低血脂和心血管事件的疗效和安全性。
N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15.